AngioDynamics Launches AMBITION BTK Trial to Evaluate Auryon Atherectomy System for Critical Limb Ischemia Treatment

Reuters
07-28
AngioDynamics Launches AMBITION BTK Trial to Evaluate Auryon Atherectomy System for Critical Limb Ischemia Treatment

AngioDynamics Inc. has announced the enrollment of the first patient in the AMBITION BTK trial, a prospective, multicenter, randomized controlled trial $(RCT)$ aimed at evaluating the clinical safety and effectiveness of the Auryon Atherectomy System when used in combination with standard balloon angioplasty. This trial focuses on treating infrapopliteal lesions in patients with Critical Limb Ischemia $(CLI.UK)$, a condition with a significant risk of limb loss if untreated. The trial will involve up to 224 patients across 30 sites, with results to be presented in the future. A companion registry will also enroll up to 1,500 additional patients who are ineligible for the RCT. Further information about the study can be found on AngioDynamics' website and ClinicalTrials.gov.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250727972766) on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10